Warrants & pre-BTD approval...Keytruda, Adstiladrin & N803+BCG, are the best treatment for BCG-Resistant patients.
Note: I did include N803+BCG because it is just a question of time for N803+BCG to get back its BTD approval status.
Keytruda with its big side effects and low CR% is not a direct competitor to TLT.
TLT-Ruvidar with no side effects and better CR% is by far superior to Keytruda.
Adstiladrin has much lower side effects, but Adstiladrin has a lower CR%(24%) compared to TLT-Ruvidar CR%(34%).
And Adstiladrin has as a very big restriction, Adstiladrin can't treat immunodeficients patients(older patients).
TLT-Ruvidar has no restrictions whatsoever and better CR%, which make TLT-Ruvidar superior to Adstiladrin.
N803+BCG 32%CR at 18 months.
TLT-Ruvidar 33%CR at 15 months.
N803+BCG CR% numbers are comparable, but there is a big difference, N803+BCG is a combo treatment, and we all know that there is a big shortage of BCG, and N803+BCG has 4 serious restrictions.
TLT-Ruvidar is a stand alone treatment and has no restrictions...TLT-Ruvidar is superior to N803+BCG.
Financing.
Research Capital Corporation(RCC).
RCC investors are investing in TLT strickly for a profit(not the science).
They usually sell the shares with a profit just to recuparate their investment, and keep the warrants for a possible future profit.
RCC investors need to know if TLT has the potential to make the warrants profitable. There is one thing that RCC investors can count on, it is the fact that Adstiladrin & N803+BCG did get the FDA BTD approval with data inferior to TLT-Ruvidar.
If TLT-Ruvidar get just the pre-BTD approval the warrants will give RCC investors a huge profit on their investment.
What are the odds that TLT will not get the pre-BTD approval?
Because TLT-Ruvidar is best in the class, has superior datas to anything out there...given time the financing will be fine.
Note:On previous public financing (not private), it took between 20-30 days to close the prospectus offering.